- Home
- AKBA vs TIPT Comparison
AKBA vs TIPT Comparison
Compare AKBA & TIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- TIPT
- Stock Information
- Founded
- AKBA 2007
- TIPT 2007
- Country
- AKBA United States
- TIPT United States
- Employees
- AKBA N/A
- TIPT N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- TIPT Property-Casualty Insurers
- Sector
- AKBA Health Care
- TIPT Finance
- Exchange
- AKBA Nasdaq
- TIPT Nasdaq
- Market Cap
- AKBA 861.7M
- TIPT 881.6M
- IPO Year
- AKBA 2014
- TIPT 2007
- Fundamental
- Price
- AKBA $2.88
- TIPT $18.55
- Analyst Decision
- AKBA Strong Buy
- TIPT
- Analyst Count
- AKBA 5
- TIPT 0
- Target Price
- AKBA $6.90
- TIPT N/A
- AVG Volume (30 Days)
- AKBA 2.9M
- TIPT 390.7K
- Earning Date
- AKBA 11-06-2025
- TIPT 10-29-2025
- Dividend Yield
- AKBA N/A
- TIPT 1.31%
- EPS Growth
- AKBA N/A
- TIPT 74.19
- EPS
- AKBA N/A
- TIPT 1.29
- Revenue
- AKBA $203,733,000.00
- TIPT $2,024,136,000.00
- Revenue This Year
- AKBA $43.91
- TIPT N/A
- Revenue Next Year
- AKBA $32.09
- TIPT N/A
- P/E Ratio
- AKBA N/A
- TIPT $14.26
- Revenue Growth
- AKBA 16.75
- TIPT 6.10
- 52 Week Low
- AKBA $1.26
- TIPT $17.80
- 52 Week High
- AKBA $4.08
- TIPT $27.41
- Technical
- Relative Strength Index (RSI)
- AKBA 47.89
- TIPT 34.10
- Support Level
- AKBA $2.83
- TIPT $17.85
- Resistance Level
- AKBA $3.02
- TIPT $18.50
- Average True Range (ATR)
- AKBA 0.12
- TIPT 1.36
- MACD
- AKBA 0.03
- TIPT -0.31
- Stochastic Oscillator
- AKBA 56.94
- TIPT 6.84
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About TIPT Tiptree Inc.
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.